在使用促性腺激素释放激素（GnRH）激动剂进行抑制的女性中，使用GnRH拮抗剂进行治疗可避免有卵巢过度刺激综合征风险的患者取消周期。
Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome.
作者信息
Gustofson Robert L, Larsen Frederick W, Bush Mark R, Segars James H
机构信息
Walter Reed Army Medical Center, National Naval Medical Center, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
出版信息
Fertil Steril. 2006 Jan;85(1):251-4. doi: 10.1016/j.fertnstert.2005.07.1291.
Forty-seven patients at high risk for ovarian hyperstimulation syndrome because of markedly elevated serum E2 levels on either long-luteal or microdose flare leuprolide acetate regimens were treated with ganirelix acetate. Despite being pretreated with GnRH agonist and without withholding gonadotropins, serum E2 decreased by 49.5% and 41.0% of pretreatment values (long luteal and microdose flare, respectively) after initiation of ganirelix, and 68.1% of the patients became pregnant.
47例因长效黄体期或微剂量激发醋酸亮丙瑞林方案导致血清E2水平显著升高而有卵巢过度刺激综合征高风险的患者接受了醋酸加尼瑞克治疗。尽管预先使用了GnRH激动剂且未停用促性腺激素，但在开始使用醋酸加尼瑞克后，血清E2分别降至预处理值的49.5%（长效黄体期）和41.0%（微剂量激发），且68.1%的患者怀孕。
Zotero 插件